icrucumab (IMC-18F1) / Eli Lilly - LARVOL DELTA

Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. (PubMed, J Chemother) - "Icrucumab did not association with an increased risk of hypertension. The RR of hypertension did not vary significantly according to the type of cancer, line of therapy, and treatment duration. The available data suggested that the use of anti-VEGF mAbs were associated with a significantly increased risk of hypertension."

Journal • P2/3 data • Retrospective data • Review • Hypertension • Oncology

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (clinicaltrials.gov) - P2; N=153; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • Monotherapy • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (clinicaltrials.gov) - P2; N=153; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Clinical • Combination therapy • Monotherapy • Trial completion • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • HER-2

[VIRTUAL] Competition between therapeutic approaches in the antiangiogenic therapy of malignant tumors (DGHO 2020) - "Approach A is represented by 5-FU or capecitabine, approach B by the anti VEGF antibody Bevacizumab, approach C by the antibodies ramucirumab and icrucumab or the tyrosíne kinase inhibitors (TKI) sorafenib and sunitinib...The combination of ramucirumab with cisplatin and fluroropyrimidines for metastatic gastric cancer (rainfall trial) (2), ramucirumab or icrucumab with capecitabine for metastatic breast cancer (3), ramucirumab with FOLFOX6 for advanced gastric cancer (4), and ramucirumab or icrucumab with FOLFOX6 for metastatic colorectal cancer (5) revealed not any advantage of the combination... The substances 5-FU and capecitabine itself have a strong antiangiogenic activity resulting in the apoptosis of endothelial cells. One has to be aware that VEGF-R is held in an endosomal storage and is released to the cell surface upon stimulation by VEGF (8). Once apoptosis of endothelial cells has started a translocation to the cell surface seems no longer possible with..."

Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

[VIRTUAL] Competition between therapeutic approaches in the antiangiogenic therapy of malignant tumors (DGHO 2020) - "Approach A is represented by 5-FU or capecitabine, approach B by the anti VEGF antibody Bevacizumab, approach C by the antibodies ramucirumab and icrucumab or the tyrosíne kinase inhibitors (TKI) sorafenib and sunitinib...The combination of ramucirumab with cisplatin and fluroropyrimidines for metastatic gastric cancer (rainfall trial) (2), ramucirumab or icrucumab with capecitabine for metastatic breast cancer (3), ramucirumab with FOLFOX6 for advanced gastric cancer (4), and ramucirumab or icrucumab with FOLFOX6 for metastatic colorectal cancer (5) revealed not any advantage of the combination... The substances 5-FU and capecitabine itself have a strong antiangiogenic activity resulting in the apoptosis of endothelial cells. One has to be aware that VEGF-R is held in an endosomal storage and is released to the cell surface upon stimulation by VEGF (8). Once apoptosis of endothelial cells has started a translocation to the cell surface seems no longer possible with..."

Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

[VIRTUAL] Competition between therapeutic approaches in the antiangiogenic therapy of malignant tumors (DGHO 2020) - "Approach A is represented by 5-FU or capecitabine, approach B by the anti VEGF antibody Bevacizumab, approach C by the antibodies ramucirumab and icrucumab or the tyrosíne kinase inhibitors (TKI) sorafenib and sunitinib...The combination of ramucirumab with cisplatin and fluroropyrimidines for metastatic gastric cancer (rainfall trial) (2), ramucirumab or icrucumab with capecitabine for metastatic breast cancer (3), ramucirumab with FOLFOX6 for advanced gastric cancer (4), and ramucirumab or icrucumab with FOLFOX6 for metastatic colorectal cancer (5) revealed not any advantage of the combination... The substances 5-FU and capecitabine itself have a strong antiangiogenic activity resulting in the apoptosis of endothelial cells. One has to be aware that VEGF-R is held in an endosomal storage and is released to the cell surface upon stimulation by VEGF (8). Once apoptosis of endothelial cells has started a translocation to the cell surface seems no longer possible with..."

Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor